Study to Evaluate the Safety and Effectiveness of the RAP Device for the Improvement in the Appearance of Cellulite

Cellulite Clinical Trial

Official title:

A Single Center Prospective Study to Evaluate the Safety and Effectiveness of the Soliton® Rapid Acoustic Pulse (RAP)™Device for the Improvement in the Appearance of Cellulite.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05199506
• Other study ID #: 2021-02
• Status: Completed
• Phase: N/A
• Start date: May 4, 2021
• Est. completion date: July 28, 2022

Study information

• Verified date: May 2023
• Source: Soliton
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this single site clinical study is to evaluate the safety and effectiveness of the Soliton Rapid Acoustic Pulse (RAP) device for the improvement of cellulite comparing two different RAP treatment doses.

Description:

This is a non-significant risk, single-center, prospective trial for safety, and efficacy using Soliton's RAP device for the improvement in the appearance of cellulite performed at 1 (one) clinical research site in the United States.

Approximately 15 healthy female participants between the age of 18-55 inclusive will be enrolled in this study.

Participants who sign the informed consent form and meet all the eligible criteria will be enrolled in the study. Each participant will undergo acoustic rapid pulse (RAP) treatments on each of the participants buttocks and legs. The participant's right buttock and leg will receive 100 Hz doses, and the participants left buttock and leg will receive 50 Hz doses.

Total study duration is anticipated to be at or less than 55 weeks from the first participant visit to the last participant observation visit. A total of 3 visits, plus two optional visits are planned for this study as listed below:

• Visit 1: Baseline/Screening (-30 Days to Day 0)

• Visit 2: Treatment (Day 0)

• Visit 3: 12-week Follow-Up Visit (+/- 14 Days)

• Visit 4: 26-week Follow-Up Visit (+/- 14 Days) (Optional)

• Visit 5: 52 Week Follow-Up Visit (+/- 14 Days) (Optional)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: July 28, 2022
• Est. primary completion date: October 21, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Seeking treatment of cellulite in the thigh and/or buttock areas

• Area of moderate to severe cellulite on thigh and/or buttock for both legs using the Cellulite Dimple - At Rest Scale at Baseline with grades of 2 or 3 based on review of photos taken under the same lightening conditions planned for the trial.

• Body Mass Index (B.M.I.) is = 30

• Participant will not have had invasive or energy-based cellulite treatments (liposuction, subcision, RF, laser, ESWT, etc.) for the prior 12 months.

• Participant will not have used topical based cellulite treatments for prior 6 months and will not use during the trial.

• Participant will not have used spray-on tanning treatments for 6 months prior to the initiation of the trial. Furthermore, participants will not use spray-on tanning treatments during the term of the trial.

• Participants must be able to provide written informed consent, understand and is willing to comply with all study related procedures and follow-up visits.

Exclusion Criteria:

• Participant is unwilling to have research photos taken of treatment areas in the presence of Sponsor's researchers.

• Participant is unwilling to have RAP treatment provided in the presence of Sponsor's researchers.

• Participant is pregnant or planning to become pregnant during the duration of the study.

• Participant is unwilling to commit to follow-up visits

• Metal or plastic implants in the area of the treatment (vascular stent, or implants in the hips, knees, etc.).

• Active electronic implants such as pacemakers, defibrillators.

• History of coagulopathy(ies) and/or on anticoagulant medication.

• Skin disorders (skin infections or rashes, extensive scarring, psoriasis, etc.) in the treatment area.

• Any surgical procedure in the treatment areas in the prior 3 months or planned during the duration of the study.

• Participant is a current smoker.

• Participant has tattoo in treatment area.

Related Conditions & MeSH terms

• Cellulite

Intervention

Device:
• RAP
Treatment of cellulite with RAP device

Locations

Country	Name	City	State
United States	The Practice of Brian Biesman	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Soliton

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessing safety	The primary safety short-term endpoint to be met if all treated participants were free from unexpected adverse events (UAEs) or serious adverse events (SAEs) attributable to the RAP treatment immediately post-treatment	Immediately post treatment
Primary	Assessing safety	The primary safety short-term endpoint to be met if all treated participants were free from unexpected adverse events (UAEs) or serious adverse events (SAEs) attributable to the RAP treatment at the short-term (12-week) visit.	12 weeks post treatment
Primary	Assessing Efficacy	The primary effectiveness objective was to demonstrate improvement in the appearance of cellulite from the 100 Hz treatment is comparable to the 50 Hz treatment. Efficacy determined by the results of a blinded independent physician assessment (IPA) panel correctly identifying the 12-week post-treatment photographs from randomly placed side-by-side comparison of before and after photographs for both treatments. The primary effectiveness endpoint will be met if the rate of correctly identified before and after photos for 100 Hz treatment is not significantly lower than the 50 Hz treatment assessment.	At 12 week follow up visit
Secondary	Assessing Participant Satisfaction	Improvement in cellulite as measured by the percentage of participants who agree or strongly agree that the final photograph of the treatment area as compared to the baseline photograph, appears improved.	At the 12 week follow up visit